Luromed LLC

Biomatrix, Inc.

Genzyme Corporation

Nancy E Larsen

Edward G Parent

Adelya K Leshchiner

Endre A Balazs

Adolf Leshchiner

Adelya Leshchiner

Edward Leshchiner

Philip A Band

Sadek K Hilal

Adelva Leshchiner

Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.

Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications

Disclosed are hydrophilic polymers such as polysaccharides, including hyaluronic acid of any origin, modified by reaction with epoxy-functional-silicones. Hydrophobic silicon, which contains chemically active groups covalently attach to the backbone of the hydrophilic polymer and gives these new, modified polymers the ability to dissolve hydrophobic compounds including oils, drugs, and vitamins, while maintaining the hydrophilic properties and benefits of the unmodified polymer. With respect to topical applications these polymers substantially increase the stability of formulations and provide for ease of preparation. The properties and advantages of the original polymer are maintained while other properties are augmented, namely the ability to combine with or dissolve hydrophobic and hydrophilic drugs. The products can be used alone or in combination with other substances for various applications including cosmetic, medical, and drug delivery applications. Also disclosed are methods for preparing them.

Modified hydrophilic polymers containing hydrophobic groups

The present invention provides for compositions of hyaluronic acid cross-linked with at least one other hydrophobic polymer to form a copolymer gel. The preferred composition is a formulation containing hyaluronic acid or its derivatives and a silicone base polymer with a functional group capable of reacting with the preferred cross-linker. The silicon may also be a group capable of undergoing further polymerization, or a silicone moiety adding to the hydrophobic nature of the gel. The product can be used alone or contain various other substances or covalently bound substances for numerous useful applications including cosmetic, medical, and drug delivery applications. The present invention also provides processes for preparing them.

Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making them

Disclosed are methods of conjugating biologically active substances, particularly, alpha-interferon, with a hyaluronan or a mixture of a hyaluronan with at least one other hydrophilic polymer having a functional group capable of reacting with divinyl sulfone. Also disclosed are stable intermediates formed by partially reacting a hyaluronan with divinyl sulfone and stopping the reaction before completion to leave free, or reactive vinyl groups on the hyaluronan molecule available for conjugation with the biologically active substance.

Hydrophilic biopolymer-drug conjugates, their preparation and use

Disclosed are biocompatible viscoelastic gel slurries formed from a polymeric gel, preferably a hyaluronan or a derivative thereof such as hylan swollen in an aqueous medium and a fluid phase which is an aqueous solution of a polymer which may also but not necessarily be a hyaluronan or derivative thereof. Also disclosed are methods of making such slurries, controlling their rheological properties and the uses thereof.

Biocompatible viscoelastic gel slurries, their preparation and use

Disclosed are drug delivery systems based on a polymeric component which is soluble or insoluble (cross-linked) hyaluronan or hyaluronan copolymerized with another hydrophilic polymer or hylan and one or more substances having biological or pharmacological activity and methods of preparing same.

Drug delivery systems based on hyaluronans derivatives thereof and their

Disclosed is hylan, a chemically modified hyaluronan preparation characterized by the presence of small amounts (0.0002-0.05% by weight) of aldehyde cross-linking groups covalently bonded to the hyaluronan molecular chains. Also disclosed is an improved method of obtaining hylan comprising treating hyaluronan in situ in animal tissues containing same with a treatment mixture including an aldehyde which is reactive towards hyaluronic acid and the proteins contained in the animal tissue. Treatment is effected at temperatures below about 16.degree. C. at very high pH, e.g., 8-14 whereby the overall yield is increased while maintaining the high molecular weight of the hylan.

Hylan preparation and method of recovery thereof from animal tissues

Percutaneous emboli are formed for therapeutic and/or corrective reasons by using a composition which includes crosslinked gells of hyaluronic acid (HA), hylan (HY) or mixed crosslinked gels of HA or HY with other materials, thrombin and cationic substances containing quaternary ammonium groups. Other optional materials include fillers and radio-opaque substances.

Growing community of inventors

Highland Mills, NY, United States of America

Nancy E Larsen